Usefulness of cilostazol versus ticlopidine in coronary artery stenting.

[1]  W. Hass,et al.  Ticlopidine, Platelets and Vascular Disease , 2011, Springer New York.

[2]  S. Pocock,et al.  A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting , 1998 .

[3]  J. Crouse,et al.  Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[4]  E. Fleck,et al.  Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. , 1998, Circulation.

[5]  M. Feldman,et al.  Thrombotic thrombocytopenic purpura after stenting and ticlopidine , 1998, The Lancet.

[6]  D. Dawson,et al.  Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. , 1998, Circulation.

[7]  Y. Ikari,et al.  Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation. , 1998, Catheterization and cardiovascular diagnosis.

[8]  M. Miyagawa,et al.  Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. , 1998, The American journal of cardiology.

[9]  P. Yarnold,et al.  Thrombotic Thrombocytopenic Purpura Associated with Ticlopidine: A Review of 60 Cases , 1998, Annals of Internal Medicine.

[10]  M. Murayama,et al.  A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. , 1997, Clinical therapeutics.

[11]  G. Jogerst,et al.  Ticlopidine‐Induced Elevated Liver Enzymes , 1997, Pharmacotherapy.

[12]  S. Takeshita,et al.  Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen. , 1997, The American journal of cardiology.

[13]  W. Halbmayer,et al.  Neutropenia with ticlopidine plus aspirin , 1997, The Lancet.

[14]  M. Hadamitzky,et al.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.

[15]  A. Colombo,et al.  A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. , 1996, Circulation.

[16]  N. Shear,et al.  Prevention of ischemic stroke. , 1995, The New England journal of medicine.

[17]  J. Carlson,et al.  Fatal Neutropenia and Thrombocytopenia Associated with Ticlopidine , 1994, The Annals of pharmacotherapy.

[18]  W Rutsch,et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.

[19]  Sadao Takahashi,et al.  Effect of Cilostazol, a Cyclic AMP Phosphodiesterase Inhibitor, on the Proliferation of Rat Aortic Smooth Muscle Cells in Culture , 1992, Journal of cardiovascular pharmacology.

[20]  B Meier,et al.  Angiographic follow-up after placement of a self-expanding coronary-artery stent. , 1991, The New England journal of medicine.

[21]  T. Nokes,et al.  The Action of Ticlopidine on Human Platelets , 1990, Thrombosis and Haemostasis.

[22]  H. Adams,et al.  A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. , 1989, The New England journal of medicine.

[23]  V. Hachinski,et al.  THE CANADIAN AMERICAN TICLOPIDINE STUDY (CATS) IN THROMBOEMBOLIC STROKE , 1989, The Lancet.

[24]  J. Maffrand,et al.  Pharmacology of Ticlopidine: A Review , 1989, Seminars in thrombosis and hemostasis.

[25]  M. Murata,et al.  Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study. , 1987, Arzneimittel-Forschung.

[26]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.

[27]  M. Hagiwara,et al.  Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. , 1988, Pharmacology.

[28]  T. Tani,et al.  Effect of cilostazol on platelet aggregation and experimental thrombosis. , 1985, Arzneimittel-Forschung.